TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval
Thursday, 4 September 2025 ()
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the most shorted stocks right now. On August 25, TD Cowen analyst Ritu Baral raised her price target on Madrigal Pharmaceuticals (NASDAQ:MDGL) to $554 from $390, while maintaining a Buy rating. The revision by the analyst followed the European…
|
||||
You Might Like |
||||
